Skip to main content
< Back to news
Methodex booth at the Cosmetorium fair which was attended by the UTOX-PCB-CERETOX research team (Photo: Methodex).
 18.10.2017

Cooperation agreement between Barcelona Science Park and clinical research company Methodex

Clinical research company Methodex has signed a collaboration agreement with the Barcelona Science Park (Parc Científic de Barcelona, PCB) with the aim of working with the Unit of Experimental Toxicology and Ecotoxicology (UTOX-PCB) to deliver comprehensive scientific, technical and marketing services that make it easier for innovative medical. 

 

UTOX-PCB was set up in 2002 as a Barcelona Science Park unit and is part of CERETOX, a technology transfer centre founded in partnership with the Department of Toxicology in the Faculty of Pharmacy at the University of Barcelona and backed by the Catalan Government’s TECNIO seal.

Today UTOX-PCB-CERETOX is a leader in public and private sector toxicology research, innovation and services in the pharmaceutical, food, cosmetics, chemical, veterinary, healthcare and environmental management industries. As toxicology is extremely multidisciplinary, the centre’s lines of expertise and technology range from traditional in vitro and in vivo toxicity studies to pharmacokinetics, ecotoxicology and nanotoxicology. Furthermore, for a number of years it has held quality accreditation for working in line with Good Laboratory Practice (GLP) principles.

Since early this year the UTOX has been consolidating its clinical pathology and histotechnology services and also driving activity in the various sectors and opening up new areas of expertise.

Now this cooperation agreement will enable it to deliver a more comprehensive safety assessment service as it will be able to offer its customers the option of continuing their clinical research with Methodex.

Methodex came out of the knowledge, experience and innovation of a number of health professionals with the intention of conducting safety and efficacy clinical trials for medical and cosmetic use products, including all clinical research and development stages and complying with regulations and good clinical practices in order to earn authorisation for marketing.

The option of doing preclinical studies at UTOX means Methodex will be able to provide its customers with the preclinical pathway through coordinating the transition to the clinical field and improving and guaranteeing even more both the global programme and also achievement of clinical targets for final marketing of medical and cosmetic use products.

“We hope that this agreement and the excellent relationship between Methodex and UTOX lead to a symbiosis which simplifies the way for companies from basic and applied research to authorisation of their products by ensuring the highest scientific and technical quality and professionalism,” said Àngel Menargues, Head of the UTOX-PCB/CERETOX-TECNIO Experimental Toxicology and Ecotoxicology Platform.